Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling. The post Novartis, Ionis Tumble On Surprise Flop For Heart Drug appeared first on Investor’s Business Daily.
Exelixis is Friday’s IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone. The post IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out…
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck’s blockbuster, Keytruda. The post Summit Packs A Punch For Merck’s Keytruda — But Not Everyone Is Sold appeared first on Investor’s Business Daily.
Climb Bio reversed course Thursday despite potential “best-in-class” data for its experimental kidney disease treatment. The post Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded appeared first on Investor’s Business Daily.
Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing. The post Ultragenyx Crashes, On Deck To Hit A Record Low, On A Shocking Failure appeared first on Investor’s Business Daily.
TG Therapeutics is Wednesday’s IBD Stock Of The Day. Shares of the multiple sclerosis biotech has topped an early entry and is near a breakout. The post IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy…
Uniqure stock wavered Wednesday after the Food and Drug Administration accepted its application for approval of a Huntington’s gene therapy. The post UniQure’s Embattled Huntington’s Gene Therapy Clears A Key Hurdle appeared first on Investor’s Business Daily.
Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies. The post Why Novartis Just Surged 6%, Eyeing A Breakout appeared first on Investor’s Business Daily.
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients. The post One Of Amgen’s Biggest Moneymakers Cuts The Risk Of Dying By 20% appeared first on…
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. The post Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers appeared first on Investor’s Business Daily.
